Assess Impact of Microdroplet Hyaluronic Acid Filler on Skin Quality in Patients on Glucagon-like Peptide-1 Agonists

Exclusion Criteria

• •1. The presence of severe facial skin aging (as defined by Modified Griffiths' Scale, with an average score of 7-9) or minimal facial skin aging (as defined by Modified Griffiths' Scale, with an average score of 0-3).
• •2. Females who are pregnant, planning a pregnancy, or currently breast feeding during the study.
• •3. Any uncontrolled systemic disease.
• •4. History of autoimmune connective tissue disease.
• •5. Current use of immunosuppressive medication.
• •6. Weight change of greater than 10% during the study period.
• •7. Significant history or current evidence of a medical, psychological or other disorder that, in the investigator's opinion, would preclude enrollment into the study.
• •8. Active dermatitis (including but not limited to atopic dermatitis, psoriasis, rosacea, acne, melasma, etc.), active infections, or other skin condition in the proposed treatment area that in the investigator's opinion might interfere with the evaluation of study parameters.
• •9. Mesotherapy; dermal fillers, biostimulator injectables; radiofrequency device treatments; microfocused ultrasound device treatments; laser and light-based device treatments; microneedling; cryolipolysis; high intensity focused electromagnetic energy device treatment; or surgery during the 12-month period before study treatment. Botulinum toxin injections (Botox, Dysport, Xeomin, Daxify, Jeuveau) during the 6-month period before study treatment.
• •10. Any investigational treatment for skin quality of the cheeks during the 12-month period before the study treatment.
• •11. Creams/cosmeceuticals and/or home therapies for the prevention or treatment of skin fine lines, wrinkles, radiance, elasticity, firmness, or smoothness in the treatment area during the 4-week period before study treatment and throughout the course of the study.
• •12. Subjects with scarring in the treatment areas. Subjects with a history of keloids will be excluded.
• •13. Subjects who spray tanned or used sunless tanners in the treatment areas 4 weeks prior to study treatment.
• •14. History of bleeding disorder, concomitant use of anticoagulants, history of connective tissue disease (e.g., lupus, scleroderma), history of Bell's Palsy, epilepsy, smoking, and/or current pregnancy or breastfeeding.
• •15. Inability to ambulate following the procedure.
• •16. History of lidocaine and/or tetracaine sensitivity deemed by the investigator to preclude subject from enrolling into study.
• •17. Individuals with known allergies or sensitivities to any of the ingredients of any topical or injectable products being used in this study.
• •18. Subjects planning any cosmetic procedure to the treatment area during the study period, other than the treatment that will be performed by the investigator.
• •19. Use of topical steroids, retinoids/retinols, or vitamin C to the face within the previous 2-weeks of screening.
• •20. Current participation or participation within 30 days prior to the start of this study in a drug or other investigational research study.